Anika Therapeutics (NASDAQ: ANIK) insider transactions
In the twelve months to 10 November 2026, executives and directors of Anika Therapeutics reported 0 open-market sales and 4 open-market purchases of 19,200 shares ($264,308), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 August 2026 | Fischetti Gary P | Director | Open-market purchase | +1,000 | $20.32 | 54,015 | Form 4 |
| 3 August 2026 | Fischetti Gary P | Director | Open-market purchase | +1,000 | $20.75 | 53,015 | Form 4 |
| 18 June 2026 | Conley Sheryl L | Director | Grant or award | +10,402 | — | 52,970 | Form 4 |
| 18 June 2026 | Capper Joseph H | Director | Grant or award | +10,402 | — | 30,805 | Form 4 |
| 18 June 2026 | Richard Stephen | Director | Grant or award | +10,402 | — | 58,273 | Form 4 |
| 18 June 2026 | Henneman John B Iii | Director | Grant or award | +10,402 | — | 65,273 | Form 4 |
| 18 June 2026 | Fischetti Gary P | Director | Grant or award | +10,402 | — | 52,015 | Form 4 |
| 3 June 2026 | Griffin Stephen D. | President and CEO | Option exercise | +12,840 | — | 49,742 | Form 4 |
| 3 June 2026 | Griffin Stephen D. | President and CEO | Shares withheld for tax | −3,769 | $14.41 | 45,973 | Form 4 |
| 1 May 2026 | Henneman John B Iii | Director | Open-market purchase | +5,000 | $14.66 | 54,871 | Form 4 |
| 30 April 2026 | Griffin Stephen D. | President and CEO | Open-market purchase | +12,200 | $12.29 | 36,163 | Form 4 |
| 15 March 2026 | McLeod Ian | SVP, CAO & Treasurer | Option exercise | +2,658 | — | 24,888 | Form 4 |
| 15 March 2026 | McLeod Ian | SVP, CAO & Treasurer | Shares withheld for tax | −781 | $14.20 | 24,107 | Form 4 |
| 15 March 2026 | Blanchard Cheryl R | Director | Option exercise | +25,131 | — | 270,892 | Form 4 |
| 15 March 2026 | Blanchard Cheryl R | Director | Shares withheld for tax | −12,104 | $14.20 | 258,788 | Form 4 |
| 15 March 2026 | Colleran David | EVP, General Counsel, Corp Sec | Option exercise | +6,449 | — | 69,463 | Form 4 |
| 15 March 2026 | Colleran David | EVP, General Counsel, Corp Sec | Shares withheld for tax | −1,893 | $14.20 | 67,570 | Form 4 |
| 14 March 2026 | McLeod Ian | SVP, CAO & Treasurer | Option exercise | +3,774 | — | 22,518 | Form 4 |
| 14 March 2026 | McLeod Ian | SVP, CAO & Treasurer | Grant or award | +1,161 | — | 23,679 | Form 4 |
| 14 March 2026 | McLeod Ian | SVP, CAO & Treasurer | Shares withheld for tax | −1,449 | $14.20 | 22,230 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Anika Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.